Previous 10 | Next 10 |
home / stock / glpgf / glpgf news
2023-08-24 10:55:38 ET More on Galapagos Galapagos NV ( GLPG ) Q2 2023 Earnings Call Transcript Galapagos to transfer drug discovery and research activities in France to NovAliX Galapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's ...
2023-08-04 16:30:18 ET Galapagos NV (GLPG) Q2 2023 Results Conference Call August 04, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commer...
Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to ...
Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief Financial Officer (C F O) and Chief Operating ...
Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-opted Dr. Susanne S chaffert as no n-executive indepe...
All 7 out of 7 eligible patients with relapsed/refractory c hronic l ymphocytic l eukemia ( rrCLL ) , with or without Richter’s T ransformation (RT) , responded to treatment (Objective Response Rate of 100%) 1 GLPG5201...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in de...
9 poster presentations and 3 abstracts publications reinforce Galapagos' commitment to immunology and the rheumatoid arthritis (RA) patient and healthcare professional community New analyses will be presented from long-term extension studies providing insights into filgotinib's ...
Mechelen, Belgium ; 5 M ay 2023 , 22 : 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ : GLPG) announced today that its B oard of D irectors created 1 , 975 , 000 ...
2023-05-05 12:47:05 ET Galapagos NV (GLPG) Q1 2023 Earnings Conference Call May 05, 2023, 08:00 ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - C...
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...